Schedule an Appointment
Directions
International
Billing
Sign Into MyChart
Ways to Help
Donate Now
Patients and Family
Patients and Family Home
Schedule an Appointment
Services and Specialties
Find a Doctor
Visiting Cincinnati Children's
Health Library
Additional Resources
Coronavirus Resources
Clinical Trials/Research Studies
Patient Resources
Vaccine Resources
Special Needs Resources
Healthcare Professionals
Healthcare Professionals Home
Services and Specialties
Clinical Trials
Find a Doctor
Refer a Patient
Additional Resources
Coronavirus Resources
Browse Careers
Patient Resources
Provider Resources
Continuing Professional Education
Clinical Training Programs
Graduate Medical Education
Clinical Laboratories
Nursing
Researchers
Research Home
Find a Researcher
Research Areas
Education and Training
Additional Resources
Shared Core Facilities
Research Support Services
Research Foundation
Funded Training
Browse Careers
Search
I want to
Find a Researcher
View Research Areas
Explore Research Training
View Shared Core Facilities
View Support Services
Read Research News
Read the Research Annual Report
View Clinical Trials
Browse Careers
Make a Donation
Schedule an Appointment
Directions
International
Billing
Sign Into MyChart
Ways to Help
Donate Now
Popular search terms
Coronavirus
Careers
Urgent Care
MyChart
Neurology
Volunteer
Oncology
Home
Researchers
Research Foundation
Annual Reports
2017 Research Annual Report
Reports
Oncology
Publications
Navigate
Close
Oncology
Featured Research
Publications
Grants
Selected Publications
Top 25 Publications from FY17 Based on Impact Factor
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA.
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
The New England journal of medicine
. 2016; 375:2550-2560.
Cavalli FMG; Remke M; Rampasek L; Peacock J; Shih DJH; Luu B; Garzia L; Torchia J; Nor C; Morrissy AS.
Intertumoral Heterogeneity within Medulloblastoma Subgroups.
Cancer Cell
. 2017; 31:737-754.e6.
Torchia J; Golbourn B; Feng S; Ho KC; Sin-Chan P; Vasiljevic A; Norman JD; Guilhamon P; Garzia L; Agamez NR.
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.
Cancer Cell
. 2016; 30:891-908.
Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ.
Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
Cancer Cell
. 2016; 30:737-749.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D.
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
Journal of Clinical Oncology
. 2016; 34:4381-4389.
Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DTW; Luu B; Cavalli FMG; Aldape K.
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
Journal of Clinical Oncology
. 2016; 34:2468-2477.
Tiao G; Geller J; Timchenko NA.
Generation of Pediatric Liver Cancer Patient-Derived Xenograft Platforms for Pediatric Liver Cancer: A Critical Stage in the Development of Anticancer Treatments.
Hepatology
. 2016; 64:1017-1019.
Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T.
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Clinical Cancer Research
. 2017; 23:2433-2441.
Ooms AHAG; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C.
Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Clinical Cancer Research
. 2016; 22:5582-5591.
Fernandez CV; Perlman EJ; Mullen EA; Chi Y-Y; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G.
Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor A Report From Children's Oncology Group AREN0532.
Annals of Surgery
. 2017; 265:835-840.
Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M.
FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.
Cancer Research
. 2016; 76:7219-7230.
Goyama S; Shrestha M; Schibler J; Rosenfeldt L; Miller W; O'Brien E; Mizukawa B; Kitamura T; Palumbo JS; Mulloy JC.
Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.
Oncogene: Including Oncogene Reviews
. 2017; 36:2589-2598.
Milewski D; Pradhan A; Wang X; Cai Y; Le T; Turpin B; Kalinichenko VV; Kalin TV.
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Oncogene: Including Oncogene Reviews
. 2017; 36:850-862.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP.
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
PLoS genetics
. 2016; 12:e1006501.
Fouladi M; Pfister SM.
MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?.
Neuro-Oncology
. 2017; 19:741-743.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ.
Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Neuro-Oncology
. 2016; 18:1319-1325.
Huibregtse KE; Vo KT; DuBois SG; Fetzko S; Neuhaus J; Batra V; Maris JM; Weiss B; Marachelian A; Yanik GA.
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with I-131-metaiodobenzylguanidine.
European Journal of Cancer
. 2016; 66:144-152.
Wagner LM; Kremer N; Gelfand MJ; Sharp SE; Turpin BK; Nagarajan R; Tiao GM; Pressey JG; Yin J; Dasgupta R.
Detection of Lymph Node Metastases in Pediatric and Adolescent/Young Adult Sarcoma: Sentinel Lymph Node Biopsy Versus Fludeoxyglucose Positron Emission Tomography Imaging-A Prospective Trial.
Cancer
. 2017; 123:155-160.
Smith EA; Gole B; Willis NA; Soria R; Starnes LM; Krumpelbeck EF; Jegga AG; Ali AM; Guo H; Meetei AR.
DEK is required for homologous recombination repair of DNA breaks.
Scientific Reports
. 2017; 7:44662.
Smith EA; Kumar B; Komurov K; Smith SM; Brown NV; Zhao S; Kumar P; Teknos TN; Wells SI.
DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma.
Oncotarget
. 2017; 8:23414-23426.
Koncar RF; Chu Z; Romick-Rosendale LE; Wells SI; Chan TA; Qi X; Bahassi EM.
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Oncotarget
. 2017; 8:15827-15837.
Dandoy CE; Hausfeld J; Flesch L; Hawkins D; Demmel K; Best D; Osterkamp E; Bracke T; Nagarajan R; Jodele S.
Rapid cycle development of a multifactorial intervention achieved sustained reductions in central line-associated bloodstream infections in haematology oncology units at a children's hospital: a time series analysis.
BMJ Quality and Safety
. 2016; 25:633-643.
Mizuno T; Fukuda T; Christians U; Perentesis JP; Fouladi M; Vinks AA.
Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.
British Journal of Clinical Pharmacology
. 2017; 83:1097-1107.
Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI.
Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
PloS one
. 2017; 12:e0177952.
Bahar M; Hashem H; Tekautz T; Worley S; Tang A; de Blank P; Wolff J.
Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience.
Journal of Neuro-Oncology
. 2017; 132:427-432.